Navigation Links
BioVex Commences OncoVEX (GM-CSF) Phase 3 Trial in Metastatic Melanoma
Date:4/14/2009

WOBURN, Mass., April 14 /PRNewswire/ -- BioVex Inc, a company developing next generation biologics for the treatment and prevention of cancer and infectious disease, announced today that its OPTiM (OncoVEX Pivotal Trial in Melanoma) Phase 3 study with OncoVEX (GM-CSF) in previously treated patients with Stage III and Stage IV melanoma had initiated. The study has commenced recruiting patients in the U.S. with sites in the United Kingdom, Germany and Australia due to open later in the year. Further details on this study can be found at www.oncovexgmcsf.com and at www.clinicaltrials.gov.

Dr Robert Coffin, Founder and Chief Technology Officer of BioVex Inc said:

"The treatment options for patients with recurrent or metastatic melanoma are currently very limited, with no therapy being approved or recognized to be effective in the second line setting and beyond. Currently, there are also very few late stage or pivotal clinical studies available for patients who have failed first line therapy. The initiation of this study, following the highly encouraging data generated in Phase 2, is therefore a significant milestone on the path towards meeting this major unmet need, and towards the approval of OncoVEX (GM-CSF) in this first indication."

OPTiM Phase 3 Trial Design

The OPTiM trial is a multi-national, open label, randomized Phase 3 study designed to assess the efficacy and safety of treatment with OncoVEX (GM-CSF) as compared to subcutaneously administered GM-CSF in patients with unresectable stage III (b-c) and Stage IV (M1a-c) disease. Patients will have received at least one prior therapy for active disease which includes any type of therapy including investigational drugs. A total of 360 patients will be enrolled (240 to
'/>"/>

SOURCE BioVex Inc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. BioVex Raises $40 Million in First Close of Series F Financing
2. BioVex to Present at the UBS Global Life Sciences Conference
3. BioVex Closes Second Round of Series E Financing
4. BioVex Appoints Genzyme Executive, Jan van Heek, as Chairman of the Board of Directors
5. BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
6. An Affiliate of JLL Partners, Inc. Commences Cash Tender Offer to Acquire PharmaNet Development Group, Inc. at $5.00 per Share
7. BVF Acquisition LLC, a Wholly-Owned Subsidiary of Biotechnology Value Fund, L.P., Commences Tender Offer for Any and All Outstanding Shares of Avigen at $1.00 Per Share
8. GlaxoSmithKline Commences Tender Offer to Acquire Genelabs Technologies, Inc.
9. SenesTech, Inc. Commences Product Registration Process With Australian Government
10. Anadys Pharmaceuticals Commences Dosing ANA773 in Hepatitis C Patients
11. Lilly Commences Cash Tender Offer for ImClone Systems at $70 Per Share
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , Sept. 18, 2014 About ... testing, is performed outside a clinical laboratory. It ... in administrating appropriate treatments and medication. POCT is ... prevalence of lifestyle diseases such as diabetes, heart ... user-friendly. POCT devices are standardized to minimize errors ...
(Date:9/18/2014)... , September 18, 2014 /PRNewswire/ ... Markets ( http://www.researchandmarkets.com/research/czvg3s/biocompatible ) has announced ... Materials - Global Strategic Business Report" ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ,This report analyzes the ... US$ Million by the following Product ...
(Date:9/18/2014)... DUBLIN , Sept. 18, 2014 ... addition of the "Global N-acetylcysteine Industry Report ... The Global N-acetylcysteine Industry Report 2014 is ... state of the global N-acetylcysteine industry. ... industry including definitions, classifications, applications and industry chain ...
(Date:9/18/2014)... 2014  U.S. biotech company Kultevat has ... for technology developed by the Donald Danforth Plant ... including for applications in production of natural rubber in ... was developed under the direction of Roger Beachy ... president of the Danforth Plant Science Center, and is ...
Breaking Biology Technology:POCT Market in China 2014-2018 2Biocompatible Materials - Global Strategic Business Report 2014 2Biocompatible Materials - Global Strategic Business Report 2014 3Global N-acetylcysteine Industry Report 2014 2Kultevat obtains license of gene switch technology 2
... (NPWH) Encourages Women to Get Informed and Ask ... growing awareness of HPV,(human papillomavirus), the primary cause of ... of Nurse Practitioners in Women,s,Health (NPWH) found that many ... prevent the disease. Despite the fact that there is ...
... Inc.,(Nasdaq: OSTE ), a leader in the emerging ... total revenue for the year,ending December 31, 2007 increased ... year ended December 31, 2006. Revenue from "core" product,lines, ... year,2007, an increase of 15% over core product revenue ...
... still flawed government-wide plan for nanotechnology risk research ... Federally-funded studies essential to managing possible risks from ... top-down strategy tied to projected commercialization, expected human ... , The National Nanotechnology Initiatives (NNI) ...
Cached Biology Technology:Survey Shows Most Women Can't Separate Fact From Fiction When It Comes to Cervical Cancer Prevention 2Survey Shows Most Women Can't Separate Fact From Fiction When It Comes to Cervical Cancer Prevention 3Survey Shows Most Women Can't Separate Fact From Fiction When It Comes to Cervical Cancer Prevention 4Osteotech Reports 2007 Full Year and Fourth Quarter Financial Results; Full Year Revenue of $104.3 Million Exceeds $100 Million Milestone; Diluted Earnings Per Share Was $.15 in 2007 2Osteotech Reports 2007 Full Year and Fourth Quarter Financial Results; Full Year Revenue of $104.3 Million Exceeds $100 Million Milestone; Diluted Earnings Per Share Was $.15 in 2007 3Osteotech Reports 2007 Full Year and Fourth Quarter Financial Results; Full Year Revenue of $104.3 Million Exceeds $100 Million Milestone; Diluted Earnings Per Share Was $.15 in 2007 4Osteotech Reports 2007 Full Year and Fourth Quarter Financial Results; Full Year Revenue of $104.3 Million Exceeds $100 Million Milestone; Diluted Earnings Per Share Was $.15 in 2007 5Osteotech Reports 2007 Full Year and Fourth Quarter Financial Results; Full Year Revenue of $104.3 Million Exceeds $100 Million Milestone; Diluted Earnings Per Share Was $.15 in 2007 6Federal nanotech risk research plan still comes up short 2
(Date:9/18/2014)... found clownfish larvae can swim up to 400 kilometres in ... cope with environmental change. , Clownfish spend their entire adult ... babies they must wander the open ocean, says study co-author, ... Coral Reef Studies (Coral CoE) at James Cook University. , ... now we,ve been given a rare glimpse into how far ...
(Date:9/17/2014)... UCLA atmospheric scientists were instrumental in the creation of ... tool to classify the fire threat potential of the ... a spark into an inferno. The index was introduced ... with UCLA and San Diego Gas and Electric. , ... to "extreme" that will be used to help fire ...
(Date:9/17/2014)... EC-FP5 four-year project, delivering its first release in 2004. ... in several EC projects, as a part of the ... BON), to increase the general awareness of the work ... dissemination of the Fauna Europaea results, the ... e-Publishing tools to prepare data papers for all 56 ...
Breaking Biology News(10 mins):Nemo's epic journey to find a new home 2UCLA scientists play key role in developing new Santa Ana Wildfire Threat Index 2Contributions on Fauna Europaea: Data papers as innovative model on expert involvement 2
... in obese laboratory rats may provide a less-invasive alternative ... Endocrinology . Scientists at Cincinnati Children,s Hospital ... of bile from the bile duct into the small ... bariatric surgeries such as gastric by-pass. They named the ...
... effect of different dosages of vitamin D supplementation in ... within a range recommended by some pediatric societies. However, ... lower range recommended by the Institute of Medicine, according ... JAMA , a theme issue on child health. ...
... From methanol to formaldehyde - this reaction is the ... Using catalysts made of gold particles, formaldehyde could be ... methods. Just how the mysterious gold catalyst works has ... the Ruhr-Universitt Bochum in a cooperation project. In the ...
Cached Biology News:Study finds possible alternative to bariatric weight loss surgery 2Optimal vitamin D dosage for infants uncertain 2Optimal vitamin D dosage for infants uncertain 3Mysterious catalyst explained 2
... functional protein microarray is the first microarray ... interactions on a proteome scale. The Yeast ... frames (ORFs) expressed as 5'-GST fusions, purified ... inch x 3 inch nitrocellulose-coated slide. With ...
... Useful for the mechanical harvesting of cells ... ensures even contact with the growth surface ... 75cm flasks • Individually wrapped • Sterilized ... This CLS number is a new product ...
... description: Designed for use with dishes and ... is a new product number, created to ... no availability yet, please order under the ... service for assistance. Comp Dim: blade L ...
... combine the proven features of the pET, ... provides all of the benefits and versatility ... backbone. The pTriEx vectors have been extensively ... in all three expression systems. In each ...
Biology Products: